SBIR/STTR Research Award
Rational Development of a Combination Nanoparticle Adjuvant for Influenza
Award amount
$599,629Program and phase
SBIR · Phase IAward year
2019Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- HDT BIO CORP
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Z33DCMWXZBK7
- Solicitation number
- Not reported
- Topic code
- NIAID
Research abstract
SignificanceHighly pathogenic avian H Ninfluenzawhich has killedpeople sinceis poised to cause a pandemic in a worldwide population that has no pre existing immunityCurrent Hvaccines are insufficiently immunogenic without the addition of adjuvantsbut responses to these adjuvanted vaccines are not durable and may not be protective against newly emergent viral strainsProposed solutionWe have developed two proprietary adjuvant technologies to enhance humoral and cellular immunityWe will incorporate these to produce a combination adjuvant optimized to augment the immunity and efficacy of an Hinfluenza immunogenThe target adjuvant profile includes promotion of a broader responseaugmentation of durable immunityandprotective efficacy against H Navian influenza
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Development of a RIG-I agonist RNA as a cure for chronic Hepatitis B
- Development of a single-dose self-amplifying RNA vaccine for boosting pre-existing influenza virus immunity, driving B and T cell responses to conserved targets
- Targeting and Imaging Ovarian Cancer with Junction Opener Conjugated-Lipid Iron Oxide Nanoparticles (JOC-LIONs)
- Development of CoroDetecT, a skin test for SARS-CoV-2 infection
- Development of an adaptable RNA vaccine against enterovirus D68 infection for the prevention of acute flaccid myelitis